Cargando…
Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease
BACKGROUND AND AIM: E6011 is a humanized monoclonal antibody targeting fractalkine (FKN), a CX3C chemokine, which regulates leukocyte trafficking during inflammation. We evaluated the safety and pharmacokinetic profile of E6011 in patients with Crohn's disease (CD) and also performed preliminar...
Autores principales: | Matsuoka, Katsuyoshi, Naganuma, Makoto, Hibi, Toshifumi, Tsubouchi, Hirohito, Oketani, Kiyoshi, Katsurabara, Toshinori, Hojo, Seiichiro, Takenaka, Osamu, Kawano, Tetsu, Imai, Toshio, Kanai, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451784/ https://www.ncbi.nlm.nih.gov/pubmed/33599356 http://dx.doi.org/10.1111/jgh.15463 |
Ejemplares similares
-
Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
por: Tanaka, Yoshiya, et al.
Publicado: (2021) -
Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2014) -
Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network)
por: Yamazaki, Hajime, et al.
Publicado: (2019) -
Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy
por: Takayama, Tetsuro, et al.
Publicado: (2015) -
Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2022)